Drugmakers Baxter International and Claris Injectables agreed to divest two pharmaceutical products to settle Federal Trade Commission antitrust concerns over Baxter's proposed $625 million acquisition of Claris' injectable drugs business.
Irish drugmaker Mallinckrodt and its U.S. subsidiary will pay $100 million to settle allegations it illegally hindered competition for a drug used to treat a rare seizure disorder in infants and then significantly raised the price of its product.
The businesses in question produce vascular closure devices, or VCDs, used to close holes in arteries following the insertion of catheters; and steerable sheaths, used to guide catheters for treating heart arrhythmias.
The Federal Trade Commission says Iowa should continue allowing physicians to determine how they will supervise assistants based on their individual practice and the physician assistant's experience. The state medical board wants stricter requirements
The Federal Trade Commission and a cadre of prominent health economists are urging Tennessee officials to reject a potential merger between Mountain States Health Alliance and Wellmont Health System.
Penn State Hershey (Pa.) Medical Center and PinnacleHealth System, Harrisburg, Pa., abandoned their proposed merger in the wake of renewed regulatory opposition from the Federal Trade Commission.
The Texas Medical Board last week withdrew its appeal against Teladoc's lawsuit that alleges the state's telemedicine rules violate federal antitrust laws, sending the dispute back to a federal trial court.
The Federal Trade Commission has recommended that Virginia regulators reject the proposed merger of two large regional systems that operate in the state: Mountain States Health Alliance and Wellmont Health System.
FTC official Mark Seidman says the deal would create a monopoly in Virginia, leading to higher prices and lower quality of care for patients.
Modern Healthcare Midwest Bureau Chief Bob Herman recently interviewed Mark Merritt, CEO of the Pharmaceutical Care Management Association, the PBM trade group, to get his take on the issues facing the industry.
Recent FTC challenges to hospital mergers have rested on its belief that limiting competition in a well-defined market would harm insurers. Actual prices or their impact on consumers and patients—the traditional grounds for antitrust challenges—barely entered into the equation.
Walgreens Boots says it will probably have to unload more stores than expected to ease antitrust concerns over its pending acquisition of Rite Aid, a deal that would make the nation's largest drugstore chain even larger.